Safety Policies & Visitor Guidelines |
Appointments & Scheduling |
Adults (18-65), Geriatrics (65+)
Adults (18-65), Geriatrics (65+)
Perelman Center for Advanced Medicine
Abramson Cancer Center, West Pavilion, 3rd Floor
3400 Civic Center Boulevard
Philadelphia, PA 19104
A facility of the Hospital of the University of Pennsylvania
The Patient Satisfaction Rating is an average of all responses to the care provider related question shown below from a 3rd party vendor, Press Ganey and as of 7/01/21, our internal platform, PMX Feedback. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.
My research focuses on clinical trials and drug development for those with early stage and metastatic breast cancer. I also seek to develop novel predictive biomarkers specifically using molecular imaging as companions to early phase trials.
Symmans WF, Yau C, Chen YY, Balassanian R, Klein ME, Pusztai L, Nanda R, Parker BA, Datnow B, Krings G, Wei S, Feldman MD, Duan X, Chen B, Sattar H, Khazai L, Zeck JC, Sams S, Mhawech-Fauceglia P, Rendi M, Sahoo S, Ocal IT, Fan F, LeBeau LG, Vinh T, Troxell ML, Chien AJ, Wallace AM, Forero-Torres A, Ellis E, Albain KS, Murthy RK, Boughey JC, Liu MC, Haley BB, Elias AD, Clark AS, Kemmer K, Isaacs C, Lang JE, Han HS, Edmiston K, Viscusi RK, Northfelt DW, Khan QJ, Leyland-Jones B, Venters SJ, Shad S, Matthews JB, Asare SM, Buxton M, Asare AL, Rugo HS, Schwab RB, Helsten T, Hylton NM, van 't Veer L, Perlmutter J, DeMichele AM, Yee D, Berry DA, Esserman LJ: Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial JAMA Oncol : 2021.
Bardia A, Hurvitz SA, DeMichele A, Clark AS, Zelnak A, Yardley D, Karuturi MS, Sanft T, Blau S, Hart L, Ma CX, Rugo HS, Purkayastha D, Moulder-Thompson S.: Phase I/II trial of exemestane, ribociclib, and everolimus in women with HR+/HER2- advanced breast cancer after progression on CDK4/6 inhibitors (TRINITI-1) Clinical Cancer Research
Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, Beckwith H, Nanda R, Albain KS, Clark AS, Kemmer K, Kalinsky K, Isaacs C, Thomas A, Shatsky R, Helsten TL, Forero-Torres A, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Asare SM, Wilson A, Singhrao R, Sit L, Hirst GL, Berry S, Sanil A, Asare AL, Matthews JB, Perlmutter J, Melisko M, Rugo HS, Schwab RB, Symmans WF, Yee D, Van't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ.: Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial Cancer Cell 39 : 989-998,2021.
Miller KD, Zhao F, Clark AS, Wilkinson G, Heineman T, Wolff A: BRACELET-1 (PrE0113): A Study To Assess Overall Response Rate By Inducing An Inflammatory Phenotype In Metastatic Breast Tumors With The Oncolytic Reovirus Pelareorep In Combination With Anti-PD-L1 Avelumab And Paclitaxel ASCO Annual Meeting 2021 : 2021.
Chein AJ, Soliman H, Ewing C, Boughey JC, Campbell MJ, Rugo HS, Schwab R, Maure M, Wong J, Wallace A, Hieken TJ, Degnim AC, Albanien KS, Goodellas C, Stringer-Reasor E, Church A, Kalinsky K, Elias A, Mitri Z, Clark AS, Nanda R, Thomas A, Han H, Isaacs C, Lang JE, Yau C, Yee D, DeMichele AM, Perlmutter J, Hilton NM, Symmans WF, Melisko ME, van't Veer LJ, I-SPY 2 Consortium, Wilson A, Lu R, Asare SM, Sanil A, Berry DA, Esserman LJ: Evaluation of Intra-tumoral (IT) SD-101 and Pembrolizumab (Pb) in combination with paclitaxel (P) followed by AC in high-risk HER2-negative (HER2-) stage II/III breast cancer: Results from the I-SPY 2 TRIAL J Clin Oncol 39 : 2021.
Takvorian SU, Parikh RB, Vader D, Wileyto EP, Clark AS, Lee DJ, Goyal G, Rocque GB, Dotan E, Geynisman DM, Full P, Spiess PE, Kim RY, Davidoff AJ, Gross CP, Miksad RA, Clip GS, Shulman LN, Mamtani E, Hubbard RA: Impact of COVID-19 pandemic on time to treatment initiation for patients with advanced cancer ASCO Annual Meeting 2021 : 2021.
Clark AS, Elmi A, McAndrew N, Wileyto EP, Shih N, Feldman M, Rosen M, Savage J, Holmes R, DiNubile N, Berger TE, Schubert E, Matthai A, Volpe M, Shah PD, Matro J, Domchek S, Mankoff D, DeMichele A: Cell cycle synchronization: Biomarker analysis in a phase I trial of alternating ribociclib and paclitaxel in advanced breast cancer AACR Annual Meeting 2021 : 2021.
McDonald ES, Pantel AR, Shah PD, Farwell MD, Clark AS, Doot RK, Pryma DA, Carlin SD.: In vivo visualization of PARP inhibitor pharmacodynamics JCI Insight
8 (8): 14692,2021.
Clark AS, Mahklin I, DeMichele A: Setting the Pick: Can PI3K inhibitors circumvent CDK 4/6 inhibitor resistance? Clinical Cancer Research : 2021.
Clark AS, Yau C, Wolf DM, Petricoin EF, Moulder SL, Wallace AM, Chien AJ, Isaacs C, Albain KS, Tripathy D, Ellis ED, Forero-Torres A, Yung R, Han HS, Lang JE, Viscusi RK, Haley BB, Kemmer K, Elias AD, Nanda R, Boughey JC, Wulfkuhle JD, Brown-Swigart L, Gallagher RI, Helsten T, Roesch E, Ewing CA, Alvarado M, Crane EP, Robinson P, Buxton M, Clennell JL, Paolini M, Asare SM, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare AL, Matthews J, Berry S, Snail A, Melissa M, Perlmutter J, Rugo HS, Schwab RB, Symmans WF, Hilton NM, Yee D, Van 't Veer LJ, Berry DA, Esserman LJ, DeMichele AM: Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2-
positive breast cancer in the adaptively randomized I-SPY2 trial Nature Communications : 2021.
Division of Hematology Oncology Perelman Center for Advanced Medicine10th Floor, South PavilionOffice #10-1543400 Civic Center Boulevard
Patient appointments: 800-789-7366
Proton therapy is a non–invasive, incredibly precise cancer treatment that uses a beam of protons moving at very high speeds to destroy cancer cells.
Our experienced cancer nurses and referral staff are here to help. Call 800-789-7366 (PENN) or complete an online request.
Learn more about the benefits of translational research at Penn Medicine.